BACKGROUND: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor indicated for type 2 diabetes mellitus (T2DM), can lower blood pressure (BP) and reduce cardiovascular mortality in patients with T2DM and preexisting cardiovascular disease. Its effects in blacks have been understudied.
mpagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that improves glycemic control in adults with type 2 diabetes mellitus (T2DM). In addition to their salutary effect in diabetes mellitus, SGLT2 inhibitors are now known to have beneficial effects on blood pressure (BP) and cardiovascular disease (CVD) risk, in particular, reduced risk of death from cardiovascular causes and hospitalization for heart failure. 1 CVD benefits are believed to be attributable to the non-glucose-lowering effects of the drug, including BP lowering, 2 which has been a consistent feature with SGLT2 inhibition. 3, 4 In addition to reducing 24-hour ambulatory BP, SGLT2 inhibitors lower body weight. 5, 6 The precise mechanism for their antihypertensive effect is not yet fully understood but is believed to depend at least in part on the drug's main renal effect (osmotic diuresis with modest obligatory natriuresis) and the accompanying reduction in extracellular volume. [7] [8] [9] Other favorable CVD outcomes have been observed as well. For example, in the EMPA-REG OUTCOME trial (Empagliflozin Removal of Excess Glucose Outcome) in adults with T2DM and established CVD, empagliflozin, when added to standard of care, reduced CVD mortality (−38%), all-cause mortality (−32%), and heart failure hospitalizations (−35%) in comparison with placebo. 1 CVD benefits were evident early in the trial and continued throughout the study. 1 Blacks are typically underrepresented in clinical trials of CVD and T2DM. 10, 11 This is unfortunate, because they are generally considered to be at high risk for hypertension and CVD in comparison with whites. [12] [13] [14] Blacks also have lower rates of BP control and a greater prevalence of resistant hypertension than whites. The REGARDS study (Reasons for Geographic And Racial Differences in Stroke) 15 reported that only 30% of black participants with T2DM and hypertension met the currently recommended target BP of <130/80 mm Hg. 16 With respect to efficacy, black patients have lower values of plasma renin activity, reduced BP responsiveness to renin-angiotensin system-blocking drugs, relatively greater BP responses to diuretics and calcium channel blockers as initial monotherapy, and a greater need for combination antihypertensive therapy. 14, 16 In light of these important issues, this study in black patients with T2DM and hypertension compared the effects of once-daily empagliflozin with matching placebo over 24 weeks with respect to glycemic control, body weight, office and ambulatory BP, safety, and tolerability.
METHODS
Full details of the design, rationale, and methodology used in this study were reported previously 17 and are summarized below.
The sponsor of the NCT02182830 study (Boehringer Ingelheim) is committed to responsible sharing of clinical study reports, related clinical documents, and patient-level clinical study data. Researchers are invited to submit enquiries via the Clinical Study Data Request website (https://www. clinicalstudydatarequest.com).
Study Design
This was a 24-week, randomized, placebo-controlled, doubleblind, parallel-group, phase 3b study performed at 92 centers in the United States (registered at ClinicalTrials.gov; unique identifier: NCT02182830). The study included a 2-week openlabel placebo run-in period, a 24-week double-blind placebo-controlled treatment period with dose escalation after 4 weeks, and a 2-week follow-up period (Figure 1 ). During the placebo run-in period, patients continued to receive their background antihyperglycemic and antihypertensive therapies. At the end of the placebo run-in, patients were randomly assigned 1:1 to receive either empagliflozin or placebo in the double-blind study period. Patients randomly assigned to empagliflozin received 10 mg empagliflozin for the first 4 weeks, after which the dose was escalated to 25 mg until week 24. After termination of the trial medication, patients were followed up for a further 2 weeks (to week 26).
The study protocol was approved by the respective Institutional Review Boards, Independent Ethics Committees, and Competent Authorities according to national and international
Clinical Perspective
What Is New?
• Despite a high prevalence of hypertension and type 2 diabetes mellitus, blacks are underrepresented in major antihyperglycemia trials; this was the first dedicated trial of a sodium-glucose cotransporter 2 inhibitor in a black patient population with type 2 diabetes mellitus and hypertension receiving 1 or more antihypertensive medications.
• Empagliflozin was associated with significant and sustained reductions in glycohemoglobin and body weight.
• Reductions in several blood pressure (BP) indicators, including mean 24-hour ambulatory systolic BP, were sustained.
What Are the Clinical Implications?
• Sodium-glucose cotransporter 2 inhibitors in general, and empagliflozin in particular, are attractive choices for glycemic control, weight reduction, and BP lowering in blacks with hypertension and type 2 diabetes mellitus.
• Sodium-glucose cotransporter 2 inhibitors improve cardiovascular outcomes in high-risk populations such as blacks, but further confirmation is needed; some of this cardiovascular disease risk reduction is likely attributable to lower BP. • The BP-lowering effect of empagliflozin started as early as 12 weeks, but was greater at week 24 than at week 12, suggesting the full BP effect may require several months of therapy to be fully manifested. 
Study Participants

Study Treatments
Patients were either drug-naive or pretreated with a stable dose (≥12 weeks) of oral antihyperglycemic treatment, which was continued during the trial. All patients were on at least 1 antihypertensive medication that was similarly held stable.
Patients received both glucose-and antihypertensive-rescue medication based on predefined criteria.
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End Points and Assessments
Patients underwent 24-hour ambulatory BP monitoring during the placebo run-in period, at week 12, and at week 24, and were required to have a successful ambulatory BP measurement before randomization. The primary end point was the between-group difference in the change from baseline in HbA1c at week 24. Key secondary end points were betweengroup differences in changes from baseline in mean 24-hour ambulatory SBP at week 12, mean trough ambulatory SBP at week 12, body weight at week 24, and trough seated (office) SBP at week 12. Diastolic BP (DBP) was evaluated in an exploratory manner. The between-group differences in mean changes from baseline in 24-hour ambulatory heart rate (HR), daytime mean ambulatory HR, nighttime ambulatory HR, and trough seated HR were analyzed as further efficacy end points. Safety end points included hypoglycemic events (plasma glucose ≤70 mg/dL [≤3.9 mmol/L] ± assistance required) and adverse events (AEs) of special interest (details in the onlineonly Data Supplement), clinical laboratory tests, orthostatic BP testing at weeks 12 and 24, and lipid parameters.
Statistical Analyses
It was calculated that having 77 patients in each treatment arm would provide a statistical power of at least 80% at the 2-sided α-level of 5% (accounting for a 20% dropout rate) for comparisons of HbA1c, BP, and body weight in the empagliflozin and placebo groups. This is based on the assumption that the difference in change from baseline versus placebo in 24-hour SBP is 5 mm Hg with a SD of 10 mm Hg (resulting in a power of 80%), and the difference in body weight is 2 kg with an SD of 2.3 kg (resulting in a power of 99%). With this sample size, the power to detect a 0.6% difference in HbA1c with a SD of 1.1% will be >85%. A hierarchical multiple testing procedure was used to evaluate superiority for the primary end point, followed by evaluation of the superiority of the key secondary end points, while maintaining the overall probability of a type I error at 0.05. The primary end point of change from baseline in HbA1c to week 24 was analyzed by using a mixed-effects model for repeated measures (MMRM) to obtain adjusted means for the treatment effects. The key secondary end points of the change from baseline in 24-hour ambulatory SBP and the change from mean trough ambulatory SBP at week 12 were analyzed via an ANCOVA approach with the last observation carried forward (LOCF) for missing data. The key secondary end points of change from baseline in body weight at week 24 and the change from baseline in trough seated SBP up to week 12 were also analyzed by using an MMRM.
A restricted maximum likelihood-based MMRM approach was used to compare the change from baseline in HbA1c at 24 weeks between the empagliflozin group and placebo group, which included fixed, categorical effect of treatment, pretreatment with metformin at screening, renal function at baseline, visit, and treatment-by-visit interaction, and the continuous, fixed covariate of baseline HbA1c and baseline HbA1c-by-visit interaction, as well. Key secondary end points, change from baseline in body weight at 24 weeks, and change from baseline in trough seated SBP (office) at week 12, were applied to a similar MMRM model as the primary end point. ANCOVA (LOCF) was used to compare the change from baseline in mean 24-hour ambulatory SBP at week 12 between the empagliflozin group and the placebo group, which included fixed, categorical effect of treatment, pretreatment with metformin at screening, renal function at baseline, and fixed continuous covariates baseline mean 24-hour ambulatory SBP, as well. A similar model was applied to the change from baseline in trough ambulatory SBP at week 12. All these analyses were prespecified in the statistical analysis plan.
Sensitivity and subgroup analyses were performed for the primary and key secondary end points. Several sensitivity During placebo run-in, eligible patients continued to receive their background antihyperglycemic therapy and antihypertensive therapy unchanged. Thereafter, patients still meeting the inclusion/exclusion criteria were randomly assigned (1:1) to receive either empagliflozin or matching placebo and entered the doubleblind period. Patients in the empagliflozin group received 10 mg empagliflozin for the first 4 weeks, after which the dose was escalated to 25 mg until week 24. Patients were followed up for 2 weeks after termination of the trial medication (ie, to week 26). Reproduced from Ferdinand et al 17 analyses were preplanned and showed the robustness of the results of primary analysis. The sensitivity analyses for the primary end point were as follows: (1) 
RESULTS
Study Patients
Between September 2014 and November 2016, 166 patients were randomly assigned to double-blind treatment. Approximately 80% of patients in both treatment groups completed the trial and trial medication. The study participant flow diagram is presented in Figure II in the online-only Data Supplement. Of 166 patients randomly assigned, 150 received study medication and had at least 1 on-treatment HbA1c measurement and, thus, were included in the full analysis set (FAS; placebo, n=72; empagliflozin 10-25 mg, n=78). Sensitivity analyses of efficacy data included the MMRM FAS (OC-IR) and comprised 150 patients: 72 placebo and 78 empagliflozin ( Table I in the online-only Data Supplement).
Demographic and baseline characteristics were generally balanced across both treatment groups, as shown in Table 1 . Overall, 52.7% were men, mean (SD) age was 56.8 (9.3) years, and mean duration of T2DM was 9.3 (7.1) years. Patients had a high mean body mass index at baseline, and high mean levels of SBP and DBP, as well. Thirty-seven percent of patients (56/150) were receiving ≥3 background antihypertensive medications. The most common type of background antihypertensive medications received were agents acting on the renin-angiotensin system (125/150, 83.3%), diuretics (71/150, 47.3%), and calcium channel blockers (62/150, 41.3%) ( 
Treatment Exposure and Compliance
Treatment exposure was comparable between groups; median exposure was 168 days for each, and mean (SD) exposure was 148.6 (48.8) days for the placebo group and 150.6 (46.6) days for the empagliflozin group. The majority of patients were exposed to >20 weeks of treatment. Treatment compliance was similar for both treatment groups; 67 of 72 (93.1%) patients in the placebo group and 75 of 78 (96.2%) patients in the empagliflozin group had an overall compliance within the accepted compliance window of 80% to 120%.
Efficacy
Primary and secondary efficacy end point data are summarized in Table 2 (and Tables IV and V in 
Glycemic Control and Body Weight
After 24 weeks of treatment, reductions in HbA1c and body weight were significantly greater with empagliflozin versus placebo (placebo-corrected differences in change from baseline: -0.78% [95% CI, -1.18 to , and treatment (P=0.0237) as fixed classification effects. BP indicates blood pressure; eGFR, estimated glomerular filtration rate; FAS, full analysis set; HbA1c, glycohemoglobin; LOCF, last observation carried forward; MMRM, mixed-effect model for repeated measures; SBP, systolic blood pressure; SE, standard error; and Wk, study week. Trough refers to treatment value 24 hours after last dose.
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*Primary end point. †The data were analyzed by using a restricted maximum likelihood-based MMRM approach on the FAS (observed cases excluding missing cases) data set. ‡Key secondary hierarchal end points (see text). §The data were analyzed by using ANCOVA FAS (LOCF), full analysis set, last observation carried forward.
Circulation. Table 2 ). Results from sensitivity and subgroup analyses supported the findings of the primary analysis (ie, HbA1c; Table I in the online-only Data Supplement) and key secondary analyses (eg, body weight).
BP End Points
Reductions from baseline to week 12 in 24-hour ambulatory SBP were significantly greater with empagliflozin than with placebo (adjusted mean Table 2 ). Empagliflozin treatment produced a reduced trough seated (office) SBP at weeks 12 and 24 ( Figure 2B and Figure III Table 2 ). DBP results showed reductions in ambulatory and seated values in the empagliflozin group versus the placebo group, with nominal P values at week 24 (Table 2) ; however, these end points were tested in an exploratory manner only. Hourly mean SBP and DBP were consistently reduced in the empagliflozin group relative to the placebo group over a 24-hour period after treatment for 12 weeks and 24 weeks (Figure 3) , with no changes in nocturnal variation in BP. Results from sensitivity and subgroup analyses supported the findings of the key secondary analyses (eg, SBP at week 12; Table VI in the online-only Data Supplement).
Patients receiving empagliflozin demonstrated significant reductions in SBP from baseline versus those receiving placebo, regardless of the time of day or sleep/ awake status. Reductions in DBP were similarly observed but were only significant for daytime and awake time parameters. BP reductions observed with empagliflozin were not associated with changes in pulse rate (at week 12, adjusted mean change from baseline in mean 24-hour ambulatory pulse rate for empagliflozin versus placebo was 1.31 beats per minute; 95% CI, -0.59 to 3.21; P=0.1742 in the FAS).
Further End Points
HR did not markedly change over the treatment period across all 4 analyses and analysis populations ( Table V in the online-only Data Supplement). Mean differences in HR changes from baseline between groups were small (<2 beats per minute differences) and were not considered to be clinically meaningful.
Safety
Safety data are summarized in Table 3 . The proportion of patients who had AEs, serious AEs, and AEs leading to the discontinuation of study drug was similar in the empagliflozin and placebo groups. Most AEs were either mild or moderate in intensity; 2 patients (2.6%) in the placebo group and 1 patient (1.3%) in the empagliflozin group experienced a severe AE. Drug-related AEs (preferred terms) with an incidence of at least 2% in any treatment group were urinary tract infection, vulvovaginal candidiasis, vulvovaginal mycotic infection, and increased serum creatinine. All serious AEs reported during the study were judged by the investigator not to be drug-related. No deaths were reported during the study.
There were slight increases in serum creatinine during the 24-week study. 
DISCUSSION
This study is the first placebo-controlled clinical trial of an SGLT2 inhibitor in a black population with T2DM and hypertension. The use of ambulatory BP monitoring is a strength of the study design that resulted in the avoidance of the problem of office hypertension (white coat effect), suggesting that these findings will be relevant to the clinical setting. By 24 weeks, empagliflozin (10-25 mg daily) therapy improved the primary end point, HbA1c (≈0.8% lower), and induced modest weight loss (≈1.2 kg). Of substantial additional interest, empagliflozin consistently lowered office and 24-hour ambulatory SBP and DBP, by about -4/-2 mm Hg greater than placebo at 12 weeks, and by about -7/-4 mm Hg greater than placebo at 24 weeks (Figure 3) . Furthermore, this effect of empagliflozin was observed 
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even though patients were already receiving at least 1 antihypertensive medication in addition to study treatment. The issue of the interaction of empagliflozin and anti-renin-angiotensin agents also deserves comment, because ≈84% of participants were continued on an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker throughout the study. When empagliflozin was added to a renin-angiotensin system-blocking drug, the BP response was very similar to that of adding a thiazide diuretic or a calcium channel blocker. Although monotherapy with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker is less effective in blacks than in whites, adding a calcium channel blocker or a thiazide to a renin-angiotensin system blocker eliminates the racial difference in response, and the second agent will demonstrate greater incremental efficacy in blacks. 18, 19 The magnitude of the BP changes reported in this study is similar to other antihypertensive agents (eg, angiotensin receptor blockers) in a predominantly white population. Also, the greater reduction in BP at week 24 in comparison with week 12 should be considered by ORIGINAL RESEARCH ARTICLE clinicians in the overall planning and management of black patients with T2DM and hypertension. Empagliflozin was well tolerated during the study period. Confirmed hypoglycemic AEs were reported in more patients receiving empagliflozin than placebo, but none of these events was severe and none required intervention or assistance. The percentage of patients with events consistent with urinary tract infection was comparable between both treatment groups. All the events consistent with urinary tract infection were mild or moderate in intensity, and none led to premature discontinuation of the study medication. The percentage of patients with events consistent with genital infection was higher with empagliflozin versus placebo; all events were mild in intensity and occurred within the first 3 months of treatment. The observed reductions in urinary albumin-to-creatinine ratio are consistent with all other empagliflozin studies. Although the changes were larger and more variable among patients with microalbuminuria and macroalbuminuria, no definitive conclusions could be made because of the relatively small numbers of patients in these subgroups. Overall, the AE profile of empagliflozin was consistent with prior safety data in the wider T2DM patient population. 20 Thus, our experience provides a clear rationale for the use of empagliflozin in black patients with T2DM and hypertension.
The results of this study show comparatively small differences between office and 24-hour mean BP values, which is in contrast with the findings of studies of antihypertensive drugs, where changes in office BP are generally greater than the corresponding 24-hour mean BP values. 21 This is often attributed to amelioration of the white coat effect by antihypertensive drugs. 21 The mechanism is unknown but is believed to represent reduced sympathetic nervous system responsiveness during antihypertensive therapy. However, the white coat effect is much more prominent in whites than in nonwhites. 22 Thus, it might be predicted that office and nonoffice BP changes would be similar in black patients during antihypertensive therapy, as shown in the present study.
The results of this study also indicate a blunting of the nocturnal decline in BP among the study population. This reduction in diurnal variation in BP (nondipping) among black subjects has been reported to occur more frequently in these individuals than other racial groups. 23 Nondipping BP has been associated with an 
increased risk of CVD events, which may result from increased sympathetic tone among these individuals, and an associated morning BP surge. Of note, a post hoc subgroup analysis from EMPA-REG BP reported that empagliflozin significantly reduced mean 24-hour SBP versus placebo in dippers and nondippers. 24 The present work extends prior observations of the BP-lowering effect of empagliflozin and other SGLT2 inhibitors to the black population. The degree of SBP lowering observed in this study is somewhat greater than that reported with empagliflozin in a predominantly white patient population with T2DM and hypertension, in which the changes from baseline to week 12 in mean 24-hour ambulatory SBP with empagliflozin 10 mg and 25 mg were -3.44 mm Hg (95% CI, -4.78 to -2.09) and -4.16 mm Hg (95% CI, -5.50 to -2.83), respectively (both P<0.001). 6 In addition, the BP results reported here were broadly similar to those observed in the EMPA-REG OUTCOME trial, 1 although this study included a limited cohort of blacks and randomly assigned only participants with established CVD. Similar SBP reductions were reported in predominantly white patient populations with canagliflozin (6-week study; n=169) 25 and dapagliflozin (12-week study; n=449). 26 BP lowering of the magnitude demonstrated in this study would be expected to be associated with benefits in terms of reductions in the risk of CVD, in particular, among black patients. A population-based cohort study demonstrated that a 1-mm Hg reduction in SBP was associated with 13.5 (95% CI, 8.8-18.2) and 9.0 (95% CI, 6.3-11.6) fewer coronary heart disease events per 100 000 person-years, in black and white populations, respectively. 27 The mechanisms for these antihypertensive effects are not fully known. The 15% decrease in uric acid levels and modest weight loss (≈1.2 kg) reported in the present study were not considered to be significant factors affecting BP. However, the BP-lowering effects of SGLT2 inhibitors are believed to be related to modest volume depletion. Diuretics in general are highly effective in lowering BP in blacks, and thiazide diuretics are now recommended as first-line antihypertensive drugs in this population. 16 It is thus not surprising that the effects of empagliflozin have an appreciable effect on BP in blacks with T2DM. Our results indicate that any reduction in blood volume related to empagliflozin administration is likely to be minor and is not accompanied by tachycardia. Empagliflozin has also been reported to reduce arterial stiffness, 28, 29 but this conclusion must be tempered by the dependence of arterial stiffness indicators on BP itself (a fact not fully discussed in prior studies). The short-term nature (12 weeks) of many studies is also problematic if one assumes that reduced stiffness represents aortic remodeling, because aortic smooth muscle cell turnover is quite slow, and aortic structure would not be expected to change very much in 3 months. 30 The cardiovascular and renal benefits of empagliflozin and other SGLT2 inhibitors are increasingly recognized. In the EMPA-REG OUTCOME trial, 1 the reduction in cardiovascular death may be partially attributable to the salutary BP benefits, but concomitant reductions occur in other established CVD risk factors, including blood glucose and body weight; changes in these risk factors with empagliflozin appear to be similar in nonblack patients. 5, 31 Underrepresentation of minority populations in clinical trials remains a significant problem. Despite the fact that blacks have a high prevalence of morbidity and mortality from CVD, they comprise only a small frac- *Investigator defined. †Serious AE data from duplicate patients (n=2) and noncompliant patients (n=3) were included; placebo 4 of 80 (5.0%) and empagliflozin 3 of 82 (3.7%).
‡Confirmed tion of participants (2% of the study population in T2DM clinical trials versus 67% for whites and 31% for Asians 10 and ≈5% of participants in recent major cardiovascular outcomes trials in T2DM 11 ). Reasons for this lack of inclusion are variable but include higher comorbidity rates (as in the Action for Health in Diabetes trial), poorer control of chronic conditions, increased safety concerns based on the higher prevalence of conditions thought to be life-limiting, and behaviors believed to predict poor study adherence. 32 Other factors that may affect participation and retention include trust issues (eg, relative lack of minority investigators and competent centers familiar with the population), logistical issues (eg, availability of transportation or child care), and a lack of knowledge about the aims and potential benefits of clinical trials. 33 It is important for a pharmaceutical trial to include representation from all subgroups likely to use that medical product because of unequal responses to a particular drug class. 34 For example, with respect to BP, blacks respond less vigorously than whites to angiotensin receptor blockers. 16, 35 Different racial groups also tend to have different risk factor profiles and may not demonstrate a uniform natural history in a particular disease, including chronic kidney disease 36 and heart failure. 37, 38 Although there is no legally enforceable requirement to include demographic subgroups in clinical trials, Section 907 of the Food and Drug Administration Safety and Innovation Act gives the US Food and Drug Administration direction to take action on this issue, and its guidance for industry was published in 2016. 39 
Study Limitations
Self-reporting of race (eg, black) and ethnicity (eg, African American) is less accurate than genealogical DNA testing, but it is currently accepted by US Food and Drug Administration guidance as the best available practice. 39 It should also be emphasized that this work does not constitute an indication for the use of empagliflozin as an antihypertensive drug. Despite its antihypertensive effects, empagliflozin is indicated for glycemic control in adults with T2DM as an adjunct to diet, exercise, and other medications, and for reducing the risk of cardiovascular death in adults with T2DM and established CVD.
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CONCLUSIONS
Empagliflozin therapy (10-25 mg once daily) was safe and well tolerated in black adults with T2DM and hypertension, and its use was associated with reduction in HbA1c and body weight, and reduction in office and ambulatory SBP and DBP, as well. This study supports the use of empagliflozin in the treatment of blacks with T2DM, especially those with hypertension. 
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